Abstract 32P
Background
This study aimed to evaluate the safety and efficacy of a combination of programmed death-1 (PD-1) inhibitor and regorafenib as second-line treatment for advanced hepatocellular carcinoma (HCC).
Methods
We retrospectively analyzed the data of 38 patients with unresectable HCC who were treated with PD-1 inhibitor in combination with regorafenib as a second-line therapy as well as the data of 32 patients treated with regorafenib only therapy as a control. The clinical data including the baseline data from blood routine test, liver function test, renal function test, tumor staging, tumor imaging features, previous treatment strategies, follow-up imaging results, and adverse events during follow-ups were recorded. The mRECIST were used to evaluate the treatment outcome of intrahepatic lesions, and the Kaplan–Meier method was used to evaluate survival time.
Results
Up to the last follow-up, the rego-PD-1 group had higher objective response rate (39.5% vs. 15.6%, P=0.028), longer progression-free survival (median 5.9 vs. 4.6 months; P=0.044), and better overall survival (OS) (median 14.5 vs. 9.5 months; P=0.041) than the regorafenib only group. Among the 38 patients treated with PD-1 inhibitor and regorafenib combination, 1 patient (2.7%) achieved complete response, 14 patients (36.8%) achieved partial response, 14 patients (36.8%) achieved stable disease, and 9 patients (23.7%) achieved progressive disease. Among the 32 patients treated with regorafenib alone, 5 (15.6%) achieved partial response, 12 (37.5%) achieved stable disease, and 15 (46.9%) achieved progressive disease. Regorafenib alone, Child–Pugh B, and presence of more than 3 tumors > 3 were independent prognostic factors for poor OS. The difference in the incidence of grade 3/4 adverse events between the two groups was not statistically significant (36.8% vs. 28.1%; P=0.439). Grade ≥3 treatment-related adverse events (TRAEs) included hypertension and diarrhea.
Conclusions
PD-1 inhibitor combined with regorafenib is a promising regimen in treating patients with unresectable HCC owing to its safety and effectiveness as well as low incidence of serious adverse events with its use.
Clinical trial identification
Editorial acknowledgement
NO
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
24P - Fibroblast growth factor receptor (FGFR) as a target for epigenetic therapies: A case review for a new approach to target tumors with somatic mutations/amplifications of FGFR
Presenter: M. Nezami
Session: Cocktail & Poster Display session
Resources:
Abstract
25P - Relationship between aberrant methylation of CpG islands of microRNA gene promoters and changes in their expression in epithelial ovarian cancer
Presenter: Irina Pronina
Session: Cocktail & Poster Display session
Resources:
Abstract
26P - 3MST: A potential workhorse in H2S signaling trimmed by microRNA-548 in breast cancer
Presenter: Alyaa Dawoud
Session: Cocktail & Poster Display session
Resources:
Abstract
29P - A phase I, open-label, dose escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics/pharmacodynamics, antitumor activity of QL1604, a humanized anti-PD-1 mAb, in patients with advanced solid tumors
Presenter: Yun Fan
Session: Cocktail & Poster Display session
Resources:
Abstract
30P - Deep learning approach for discovering new predictive histological features of immunotherapy response
Presenter: Saima Ben Hadj
Session: Cocktail & Poster Display session
Resources:
Abstract
33P - Nomogram to predict survival of patients with unresectable melanoma receiving immune checkpoint inhibitors
Presenter: Eftychia Chatziioannou
Session: Cocktail & Poster Display session
Resources:
Abstract
34P - Targeting LSD1 rescues MHC-I antigen presentation and overcomes resistance to PD-L1 checkpoint blockade in small cell lung cancer
Presenter: Evelyn Nguyen
Session: Cocktail & Poster Display session
Resources:
Abstract
36P - Therapeutic vaccination with HPV-16 oncoproteins fused into a checkpoint modifier of early T cell activation protects against HPV-associated tumors in a preclinical model
Presenter: Susan Currie
Session: Cocktail & Poster Display session
Resources:
Abstract
37P - Dose transition pathways for time-to-event continual reassessment method (TITE-CRM): Will imposing a waiting time result in better performance?
Presenter: Zhulin Yin
Session: Cocktail & Poster Display session
Resources:
Abstract
38P - Locoregional radiotherapy improves survival outcomes in de novo metastatic nasopharyngeal carcinoma treated with chemoimmunotherapy
Presenter: Yujun Hu
Session: Cocktail & Poster Display session
Resources:
Abstract